{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:50:59Z","timestamp":1792176659286,"version":"4.4.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.clinthera.2021.03.015","type":"journal-article","created":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T01:58:29Z","timestamp":1622253509000},"page":"822-835.e16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies"],"prefix":"10.1016","volume":"43","author":[{"given":"Jitsu","family":"Kato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Kuroha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kakehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Wasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Ohwada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.03.015_bib0001","series-title":"IASP Terminology. Vol 2020. 2018 ed.","year":"2018"},{"key":"10.1016\/j.clinthera.2021.03.015_bib0002","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.mayocp.2015.01.018","article-title":"Neuropathic pain: principles of diagnosis and treatment","volume":"90","author":"Gilron","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clinthera.2021.03.015_bib0003","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.pain.2013.11.013","article-title":"Neuropathic pain in the general population: a systematic review of epidemiological studies","volume":"155","author":"van Hecke","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2021.03.015_bib0004","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/ejp.977","article-title":"The prevalence and impact of chronic neuropathic pain on daily and social life: a nationwide study in a Japanese population","volume":"21","author":"Inoue","year":"2017","journal-title":"Eur J Pain"},{"key":"10.1016\/j.clinthera.2021.03.015_bib0005","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00540-018-2501-0","article-title":"Executive summary of the Clinical Guidelines of Pharmacotherapy for Neuropathic Pain: second edition by the Japanese Society of Pain Clinicians","volume":"32","author":"Sumitani","year":"2018","journal-title":"J Anesth"},{"key":"10.1016\/j.clinthera.2021.03.015_bib0006","doi-asserted-by":"crossref","first-page":"17002","DOI":"10.1038\/nrdp.2017.2","article-title":"Neuropathic pain","volume":"3","author":"Colloca","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.clinthera.2021.03.015_bib0007","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1055\/s-0038-1673679","article-title":"Neuropathic pain","volume":"38","author":"Macone","year":"2018","journal-title":"Semin Neurol"},{"key":"10.1016\/j.clinthera.2021.03.015_bib0008","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3109\/15360288.2013.816408","article-title":"Therapeutic options for the treatment of postherpetic neuralgia: a systematic review","volume":"27","author":"Khadem","year":"2013","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"10.1016\/j.clinthera.2021.03.015_bib0009","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1111\/pme.12845","article-title":"Suboptimal treatment of diabetic peripheral neuropathic pain in the United States","volume":"16","author":"Yang","year":"2015","journal-title":"Pain Med"},{"key":"10.1016\/j.clinthera.2021.03.015_bib0010","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2021.03.015_bib0011","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1080\/14737175.2016.1202764","article-title":"Alpha(2)delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use","volume":"16","author":"Calandre","year":"2016","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.clinthera.2021.03.015_bib0012","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1523\/JNEUROSCI.0356-09.2009","article-title":"The increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin","volume":"29","author":"Bauer","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.clinthera.2021.03.015_bib0013","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1124\/jpet.117.247551","article-title":"Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the \u03b1(2)\u03b4 subunit of voltage-gated calcium channels","volume":"365","author":"Domon","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2021.03.015_bib0014","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00210-019-01628-z","article-title":"Analgesic effects of mirogabalin, a novel ligand for \u03b1(2)\u03b4 subunit of voltage-gated calcium channels, in experimental animal models of fibromyalgia","volume":"392","author":"Saeki","year":"2019","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.clinthera.2021.03.015_bib0015","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/jdi.13013","article-title":"Mirogabalin for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase III study in Asian patients","volume":"10","author":"Baba","year":"2019","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.clinthera.2021.03.015_bib0016","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/j.pain.0000000000001501","article-title":"Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients","volume":"160","author":"Kato","year":"2019","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2021.03.015_bib0017","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40265-019-01070-8","article-title":"Mirogabalin: first global approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2021.03.015_bib0018","series-title":"Japan Society of Pain Clinicians, ed. Vol 2020","author":"Committee for the Guidelines for the Pharmacologic Management of Neuropathic Pain. Guidelines for the pharmacologic management of neuropathic pain","year":"2016"},{"key":"10.1016\/j.clinthera.2021.03.015_bib0019","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/biomet\/90.1.53","article-title":"Pattern-mixture models with proper time dependence","volume":"90","author":"Kenward","year":"2003","journal-title":"Biometrika"},{"key":"10.1016\/j.clinthera.2021.03.015_bib0020","series-title":"Wiley Classics Library Edition","article-title":"Multiple imputation for nonresponse in surveys","author":"Rubin","year":"1987"},{"key":"10.1016\/j.clinthera.2021.03.015_bib0021","doi-asserted-by":"crossref","first-page":"e00418","DOI":"10.1002\/prp2.418","article-title":"Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: results from phase 1 studies","volume":"6","author":"Brown","year":"2018","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.clinthera.2021.03.015_bib0022","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.2337\/dc14-1044","article-title":"Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study","volume":"37","author":"Vinik","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2021.03.015_bib0023","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/jcph.974","article-title":"Pharmacokinetics and safety of a single oral dose of mirogabalin in Japanese subjects with varying degrees of renal impairment","volume":"58","author":"Kato","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2021.03.015_bib0024","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.2147\/JPR.S255345","article-title":"Mirogabalin in Japanese patients with renal impairment and pain associated with diabetic peripheral neuropathy or post-herpetic neuralgia: a phase III, open-label, 14-week study","volume":"13","author":"Baba","year":"2020","journal-title":"J Pain Res"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821001272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821001272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:55:15Z","timestamp":1758963315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821001272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0149291821001272"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.03.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}